Status:
UNKNOWN
CMV Infection and Immune Intervention After Transplantation
Lead Sponsor:
Peking University People's Hospital
Conditions:
CMV Viremia
Transplantation Infection
Eligibility:
All Genders
16-65 years
Phase:
NA
Brief Summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective or even the only way to cure blood malignant diseases. Cytomegalovirus (CMV) infection is a serious early complication of...
Eligibility Criteria
Inclusion
- Patients with acute leukemia (AL) or myelodysplastic syndrome (MDS) or myeloma or lymphoma undergoing haploidentical allogeneic stem cell transplantation
- No CMV infection by 20 days ± 3 days after transplantation
- No active acute GVHD by 20 days ± 3 days after transplantation
- The dose of prednisolone was less than 0.5mg / kg / d within 72 hours before and after infusion of NK cells
- Prior to transplantation, the CMV IgG of the recipient and donor were positive, and the recipient had a suitable donor to expand NK cells.
- Patient age 16-65 years
- Donor age 16-65 years
- Patient Karnofsky score\> 70%
- Estimated survival\> 3 weeks
- Patient agrees to participate in study
Exclusion
- Participants in any other clinical trials within 1 month before enrollment
- Active infection
- HBV or HCV or HIV carriers
- With moderate to severe renal dysfunction (blood creatinine\> 130umol / L) and / or liver dysfunction (total bilirubin\> 34umol / L, ALT, AST\> 2 times the upper limit of normal) before NK infusion
- Researchers do not consider it appropriate to participate in this trial.
Key Trial Info
Start Date :
March 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04320303
Start Date
March 23 2020
End Date
December 31 2021
Last Update
June 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Institute of Hematology
Beijing, Beijing Municipality, China, 100044